drugset / Trial / NCT06729320

A Randomized Controlled, Open, Single-center Clinical Study Evaluating the Efficacy and Safety of Umbilical Cord Blood Mononuclear Cells in Patients with Refractory Immune Effector Cell-related Hemocytopenia

NCT06729320

Not yet recruiting 40 enrolled Beijing GoBroad Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study was to evaluate the safety and efficacy of umbilical cord blood mononuclear cell in the treatment of refractory immune effector cell-related hemocytopenia by observing the efficacy related factors and adverse reactions.

Timeline

Start
2024-12-01
Primary completion
2025-06-01
Completion
2025-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Umbilical cord blood mononuclear cells Cell therapy 3e+08 cells Intravenous